Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Srđan Verstovšek, Ruben A. Mesa, Robert A. Livingston, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 19

Showing 19 citing articles:

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
Tanvi Verma, Nikolaos Papadantonakis, Deniz Peker Barclift, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 514-514
Open Access | Times Cited: 6
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 13
Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti‐cancer agents
Tomiko Sunaga, Takahiro Okada, Yoshitaka Iso, et al.
ESC Heart Failure (2025)
Open Access
Sometimes Small Is Beautiful: Discovery of the Janus Kinases (JAK) and Signal Transducer and Activator of Transcription (STAT) Pathways and the Initial Development of JAK Inhibitors for IBD Treatment
Jonathan D. Kaunitz
Digestive Diseases and Sciences (2025)
Open Access
Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta‐Analysis of Cardiovascular Safety
Roberta Dunn, Edouard Long, L. Gagnon, et al.
eJHaem (2025) Vol. 6, Iss. 1
Open Access
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Nature Medicine (2025)
Open Access
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)
Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Cancer (2025) Vol. 131, Iss. 7
Open Access
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib
Liesl Butler, Cecily Forsyth, Claire Harrison, et al.
eJHaem (2025) Vol. 6, Iss. 2
Open Access
Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs
Chaoyi Wei, Hein Than, Feng‐Ju Huang, et al.
Hematological Oncology (2025) Vol. 43, Iss. S1
Open Access
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study
Lucía Pérez‐Lamas, Álvaro Díaz‐González, Regina García Delgado, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera
Anders Lindholm Sørensen, Vibe Skov, Lasse Kjær, et al.
Blood Advances (2024) Vol. 8, Iss. 20, pp. 5416-5425
Open Access | Times Cited: 2
Combination of JAK inhibitor and immune checkpoint inhibitor in clinical trials: a breakthrough
Shiqing Dong, Zhongnan Ma
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных новообразований (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2024 г.)
Анаит Левоновна Меликян, Irina N. Subortseva, А. М. Ковригина, et al.
Clinical oncohematology (2024) Vol. 17, Iss. 3, pp. 291-334
Open Access | Times Cited: 1
Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial
Kazuya Shimoda, Norio Komatsu, Itaru Matsumura, et al.
International Journal of Hematology (2024) Vol. 120, Iss. 3, pp. 314-324
Open Access | Times Cited: 1
Implications of Iron in Ferroptosis, Necroptosis, and Pyroptosis as Potential Players in TBI Morbidity and Mortality
M. J. Nolt, James R. Connor
ASN NEURO (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
Mario Tiribelli, Gianluca Morelli, Massimiliano Bonifacio
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 743-754
Closed Access
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety
Lucia Masárová, John Mascarenhas, Raajit K. Rampal, et al.
Cancer (2024)
Closed Access
Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
Olga Golovina, Н. Н. Силина, N. Korsakova, et al.
Sechenov Medical Journal (2024) Vol. 15, Iss. 3, pp. 26-35
Open Access
Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia
Somedeb Ball, Najla H Al Ali, Akriti G Jain, et al.
Frontiers in Hematology (2024) Vol. 3
Open Access
Prognostic significance of LOXL2 enzyme activity in primary myelofibrosis
Guoqing Lv, Wenting Lv
Medicine (2024) Vol. 103, Iss. 49, pp. e40924-e40924
Open Access
A Review of Real-World Experience With Ruxolitinib for Myelofibrosis
Haifa Kathrin Al‐Ali, Aaron T. Gerds, Michael R. Grunwald, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
Page 1

Scroll to top